Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,347 result(s) found. Displaying page 275 of 2,218.
    «« First « Previous 271  272  273  274  275  276  277  278  279  Next» Last»»
    EudraCT Number: 2014-005042-21 Sponsor Protocol Number: I4X-MC-JFCU Start Date*: 2015-04-21
    Sponsor Name:Eli Lilly and Company
    Full Title: A Single-Arm, Multicenter, Phase 1b Study with an Expansion Cohort to Evaluate Safety and Efficacy of Necitumumab in Combination with Abemaciclib in Treatment of Patients with Stage IV Non-Small Ce...
    Medical condition: Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-001275-80 Sponsor Protocol Number: X358605 Start Date*: 2016-08-25
    Sponsor Name:XOMA (US) LLC
    Full Title: An Open-Label Study of XOMA 358, with Optional Dose Escalation, in Patients with Congenital Hyperinsulinism
    Medical condition: Hypoglycemia associated with congenital hyperinsulinism
    Disease: Version SOC Term Classification Code Term Level
    19.0 10027433 - Metabolism and nutrition disorders 10077227 Hyperinsulinemic hypoglycemia LLT
    19.0 10027433 - Metabolism and nutrition disorders 10020644 Hyperinsulinism NOS LLT
    19.0 10027433 - Metabolism and nutrition disorders 10061211 Hyperinsulinism PT
    19.0 10027433 - Metabolism and nutrition disorders 10022484 Insulin hypoglycaemia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005499-46 Sponsor Protocol Number: Heparc-2008 Start Date*: 2016-06-24
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Multicenter, Open-Label Study to Evaluate ARC-520 Administered Alone and in Combination with Other Therapeutics in Patients with Chronic Hepatitis B Virus (HBV) Infection (MONARCH)
    Medical condition: Chronic Hepatitis B Virus (HBV) Infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004617-28 Sponsor Protocol Number: Start Date*: 2017-11-30
    Sponsor Name:The University of Manchester
    Full Title: A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination with Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy as Second-Line Therapy for Advanced/Metastatic Endometria...
    Medical condition: Advanced or recurrent endometrial carcinoma or carcinosarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-003968-39 Sponsor Protocol Number: 2015CA02 Start Date*: 2017-09-19
    Sponsor Name:University of Dundee/NHS Tayside
    Full Title: Renal and Cardiovascular Effects of SGLT2 inhibition in combination with loop diuretics in diabetic patients with chronic heart failure.
    Medical condition: Type 2 diabetes and heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    20.0 100000004849 10010684 Congestive heart failure LLT
    20.0 100000004849 10019279 Heart failure LLT
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003902-14 Sponsor Protocol Number: EORTC-1741-GITCG Start Date*: Information not available in EudraCT
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: DKN-01/atezolizumab as second line treatment of biliarY tract cancer and in combiNAtion or not with paclitaxel as second line treatMent of esophagogastrIC cancer: a multi-center Phase II Trial
    Medical condition: Non-operable biliary tract cancer (BTC) and non-operable esophagogastric cancer (EGC) adenocarcinoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061203 Hepatobiliary neoplasm PT
    20.0 10019805 - Hepatobiliary disorders 10019817 Hepatobiliary neoplasms NEC HLT
    20.0 10019805 - Hepatobiliary disorders 10019811 Hepatobiliary neoplasms HLGT
    20.0 10019805 - Hepatobiliary disorders 10019805 Hepatobiliary disorders SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019814 Hepatobiliary neoplasms malignancy unspecified HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019815 Hepatobiliary neoplasms malignant and unspecified HLGT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056267 Gastroesophageal cancer LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    20.0 10017947 - Gastrointestinal disorders 10017812 Gastric neoplasms malignant HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017991 Gastrointestinal neoplasms malignant and unspecified HLGT
    20.0 10017947 - Gastrointestinal disorders 10017990 Malignant and unspecified neoplasms gastrointestinal NEC HLGT
    20.0 10017947 - Gastrointestinal disorders 10017947 Gastrointestinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CY (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002635-41 Sponsor Protocol Number: 15HI53 Start Date*: 2018-09-26
    Sponsor Name:Great Ormond Street Hospital
    Full Title: A paediatric phase I/II study of intermittent dosing of the MEK-1 inhibitor selumetinib in children with neurofibromatosis type-1 and inoperable plexiform neurofibroma and/or progressive optic path...
    Medical condition: Neurofibromatosis type 1 associated plexiform neurofibromas Neurofibromatosis type 1 associated progressive or relapsed optic pathway glioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10029270 Neurofibromatosis, type 1 (von Recklinghausen's disease) LLT
    20.0 100000004864 10065866 Plexiform neurofibroma LLT
    20.0 100000004864 10030935 Optic nerve glioma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-005336-23 Sponsor Protocol Number: Baby-OSCAR Start Date*: 2014-12-16
    Sponsor Name:University of Oxford
    Full Title: Outcome After Selective Early Treatment for Closure of Patent Ductus Arteriosus in Pre-term Babies
    Medical condition: Patent ductus arteriosus of the newborn
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-000826-13 Sponsor Protocol Number: MDCO-APO-15-01 Start Date*: 2016-01-20
    Sponsor Name:The Medicines Company
    Full Title: A placebo-controlled, double-blind, randomized trial to compare the effect of treatment on plaque burden as determined by intravascular ultrasound and to evaluate the efficacy, pharmacokinetics, sa...
    Medical condition: acute coronary syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004441-17 Sponsor Protocol Number: CFAM810B2303 Start Date*: 2016-04-12
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: A Multicenter, Open-label, Single-arm, Two-step Study to Evaluate the Safety and Single-dose Pharmacokinetics of Famciclovir and Multiple-dose Safety After Administration of Famciclovir Oral Pediat...
    Medical condition: Herpes Simplex
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-001119-19 Sponsor Protocol Number: A0661206 Start Date*: 2016-04-13
    Sponsor Name:Pfizer Inc.
    Full Title: Ocular Effects Of Azithromycin Oral Solution In Pediatric Patients With Pharyngitis/tonsillitis
    Medical condition: pharyngitis/tonsillitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10034835 Pharyngitis PT
    19.0 10021881 - Infections and infestations 10044008 Tonsillitis PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002924-99 Sponsor Protocol Number: NL.58160.091.16 Start Date*: 2016-10-27
    Sponsor Name:Radboudumc
    Full Title: The effectiveness of deep versus moderate neuromuscular blockade during laparoscopic donor nephrectomy in enhancing postoperative recovery.
    Medical condition: Live kidney donation is currently the most effect strategy to manage the shortage of donor kindeys for transplantation. Optimizing the safety and postoperative recovery after laparoscopic donornep...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-003250-41 Sponsor Protocol Number: 1 Start Date*: 2015-09-15
    Sponsor Name:Public Health England
    Full Title: Protection induced by Live Attenuated Influenza Vaccine (LAIV or Fluenz Tetra) - applied epidemiological study
    Medical condition: There is no medical condition associated with this trial. The trial involves vaccination of healthy children with a licensed product according to the SmPC. The vaccination is Fluenz Tetra, a live...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10016794 Flu vaccination LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004654-17 Sponsor Protocol Number: GECP18/03 Start Date*: 2019-04-02
    Sponsor Name:Fundación GECP
    Full Title: A phase II open-label study of Atezolizumab in combination with bevacizumab as first line treatment for locally advanced or metastatic high-intermediate tumour mutation burden (TMB) selected non-sq...
    Medical condition: Non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001669-17 Sponsor Protocol Number: 18GS001 Start Date*: 2018-08-28
    Sponsor Name:Nottingham University Hospitals NHS Trust
    Full Title: ICaRAS (IV Iron for Cancer Related Anaemia Symptoms) – A Feasibility Study of Intravenous Iron Therapy for Anaemia in Palliative Cancer Care.
    Medical condition: Iron deficiency anaemia secondary to cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002062 Anaemia iron deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-005279-25 Sponsor Protocol Number: LP0058-1072 Start Date*: 2016-06-22
    Sponsor Name:LEO Pharma A/S
    Full Title: LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris A phase 2a proof of concept study comparing an oral tablet formulation of LEO 32731 with a corresponding placebo tablet in pati...
    Medical condition: Psoriasis Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002628-14 Sponsor Protocol Number: I1F-MC-RHBQ Start Date*: 2016-06-08
    Sponsor Name: [...]
    1.
    2. Eli Lilly and Company
    Full Title: A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Versus Placebo in Patients with Moderate-to-Severe Genital Psoriasis
    Medical condition: Moderate-to-severe genital psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10063407 Psoriasis genital LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005776-24 Sponsor Protocol Number: MRY-IIA-2015-01 Start Date*: 2016-10-27
    Sponsor Name:Dr. Manuel Rodríguez Yáñez
    Full Title: Intensive treatment of blood pressure in acute ischemic stroke. TICA 2 study.
    Medical condition: Acute ischemic stroke
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10055221 Ischemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000892-33 Sponsor Protocol Number: ZP4207-17086 Start Date*: 2019-01-29
    Sponsor Name:Zealand Pharma A/S
    Full Title: A phase 3, randomized, double-blind, placebo- and active-controlled, parallel-arm trial to assess the efficacy, safety, and pharmacokinetics of dasiglucagon relative to placebo and GlucaGen® when a...
    Medical condition: Type 1 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2014-003873-41 Sponsor Protocol Number: 14-23-16/07 Start Date*: 2015-07-09
    Sponsor Name:MAASTRO Clinic
    Full Title: Non invasive imaging of tumor hypoxia with [18F]HX4 Positron-Emission-Tomography (PET): A phase II trial
    Medical condition: Eligible patients with histologically/cytologically proven primary tumors of the prostate, esophagus, brain or rectum or metastatic disease to the brain (originating from breast, lung or colorectal...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 271  272  273  274  275  276  277  278  279  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 10:51:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA